Renaissance Capital logo

BIOLIFE4D Filed, US Offering, Removed, Nasdaq: SAVU

Developing synthetic human hearts by utilizing 3D bioprinting technology.

Industry: Health Care

BIOLIFE4D CORPORATION is a pioneering biotech company that plans to leverage current advances in life sciences and cardiac tissue engineering to build human hearts suitable for implantation – potentially lifesaving technology that ultimately gives patients the gift of time. Operated by seasoned business leaders and guided by world-class biomedical engineers and life sciences experts, we are driving a movement to transform the treatment of heart disease which is the leading cause of death among both men and women globally. We are committed to perfecting the technology to make viable organ replacement an accessible and affordable reality, as well as mini-hearts for cardiotoxicity testing. We believe that our groundbreaking approach converges recent breakthroughs in regenerative medicine, adult stem cell biology, 3D printing techniques, and computing technology that could make organ replacement commercially viable and commonplace globally. We plan to create a patient-specific, fully functioning heart through 3D bioprinting using the patient’s own cells – eliminating the well-known challenges of organ rejection and long donor waiting lists that plague existing organ transplant methods.
IPO Data
IPO File Date 06/03/2022
Offer Price
Price Range $5.20 - $7.20
Offer Shares (mm) 1.6
Deal Size ($mm) $10
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
Aegis Capital Corp.
Company Data
Headquarters Buffalo Grove, IL, United States
Founded 2016
Employees at IPO 12
Website biolife4d.com

BIOLIFE4D (SAVU) Performance

Created with Highcharts 10.3.2Chart context menuSAVU vs. IPO Index (IPOUSA)16. Dec23. Dec30. Dec6. Jan13. Jan20. Jan27. Jan3. Feb10. Feb17. Feb24. Feb3. Mar10. Mar-20%-10%0%-30%+ 10%View 5 days5dView 1 month1mView 3 months3mView year to dateYTDView 1 year1yView allAllRenaissance IPO IndexOur ETF tracks the IPO Index